Ann: Quarterly Report - December 2015, page-4

Dak - I respect what you have to say and it's not for me to try and turn your opinion around, but have you talked with management about your concerns? You've obviously felt strongly about this for a while. Did you make the effort to attend the AGM where you could hear directly from management, ask questions and chat with fellow investors like myself?

This report was always going to carry the baggage of Medivet and the next half yearly will too. The Jan-Jun 2016 accounts will be the first set of clean accounts (without Medivet) where investors will be able to judge the company in its new state.

Personally I'm not expecting much appreciation in the share price until -
(1) there is a clean set of accounts showing good organic growth and a profitable company (rather than a theoretical profit as is the case now) ; and
(2) there is a value-adding acquisition enhancing the growth of the company.

I'd agree the marketing side to investors could improve with a presentation periodically released to the market telling them about MLA and why they should invest (which could only help the share price too).